Disc Medicine is a clinical-stage biopharmaceutical brand dedicated to developing new therapies for patients with inherited and acquired anemias. They focus on restoring regulation of hepcidin, which is the link between genetics and erythropoiesis, to provide innovative treatments for rare blood disorders. With a vision to make a meaningful impact on the lives of patients and their families, Disc Medicine is committed to translating scientific discoveries into practical therapies.

Their pipeline includes promising treatments such as Bitopertin and DISC-0974, aimed at potentially saving lives, alleviating suffering, and enabling patients to lead vibrant lives. The brand draws motivation from their talented team of scientists and industry veterans, who are inspired by their shared drive, tireless dedication, and desire to make a difference. Disc Medicine is actively involved in various investor conferences and regularly publishes updates on clinical trials and financial results